Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma
Shi-Zhe Zhang, Xiao‐Dong Zhu, Long-Hai Feng, et al.
Experimental Hematology and Oncology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
Xuhui Bao, Yongjun Liang, Hanman Chang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 59
S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway
Yan Sun, Huan Zhang, Junpeng Meng, et al.
Cell Reports (2022) Vol. 40, Iss. 7, pp. 111194-111194
Closed Access | Times Cited: 66
Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Xiao-dan Xia, Zhongsheng Peng, Hongmei Gu, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 65
Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells
Rui Wang, Hongchuan Liu, Peng He, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 40
Self-Assembly of a Multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and Pcsk9 siRNA Potentiate Immune Checkpoint Therapy for Colorectal Cancer
Wenjing Guo, Huabin Gao, Hui Li, et al.
ACS Applied Materials & Interfaces (2022) Vol. 14, Iss. 28, pp. 31634-31644
Open Access | Times Cited: 39
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study
Si Fang, James Yarmolinsky, Dipender Gill, et al.
PLoS Medicine (2023) Vol. 20, Iss. 1, pp. e1003988-e1003988
Open Access | Times Cited: 35
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner
Weijian Wang, Qibo Huang, Zhibin Liao, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma
Deming Li, Ting Zhang, Ye Guo, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 7
Open Access | Times Cited: 12
Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities
Wen G. Jiang, Weilin Jin, Aman Xu
International Journal of Biological Sciences (2024) Vol. 20, Iss. 6, pp. 2044-2071
Open Access | Times Cited: 9
Polymeric Polylactic Acid–Glycolic Acid-Based Nanoparticles Deliver Nintedanib Across the Blood–Brain Barrier to Inhibit Glioblastoma Growth
Ying Dang, Zhi‐Wen Zhao, Bo Wang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 443-443
Open Access | Times Cited: 1
The Role of Cholesterol Metabolism and Its Regulation in Tumor Development
Yongmei Wu, Wenqian Song, Su Min, et al.
Cancer Medicine (2025) Vol. 14, Iss. 7
Open Access | Times Cited: 1
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
A. Bhattacharya, Abhirup Chowdhury, Koel Chaudhury, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 1, pp. 188581-188581
Closed Access | Times Cited: 45
Insight into the Evolving Role of PCSK9
Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, et al.
Metabolites (2022) Vol. 12, Iss. 3, pp. 256-256
Open Access | Times Cited: 32
The evolving landscape of PCSK9 inhibition in cancer
Palak P. Oza, Khosrow Kashfi
European Journal of Pharmacology (2023) Vol. 949, pp. 175721-175721
Open Access | Times Cited: 22
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
Yan Gu, Xiaozeng Lin, Ying Dong, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 21
In-depth quantitative proteomics analysis revealed C1GALT1 depletion in ECC-1 cells mimics an aggressive endometrial cancer phenotype observed in cancer patients with low C1GALT1 expression
Ana Montero‐Calle, Álvaro López‐Janeiro, Marta Mendes, et al.
Cellular Oncology (2023) Vol. 46, Iss. 3, pp. 697-715
Open Access | Times Cited: 18
Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer
Qi‐Chao Yang, Shuo Wang, Yuan‐Tong Liu, et al.
iScience (2023) Vol. 26, Iss. 6, pp. 106916-106916
Open Access | Times Cited: 14
Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy
Hanbing Wang, Xin Zhang, Yipeng Zhang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
MRG15 aggravates sepsis-related liver injury by promoting PCSK9 synthesis and secretion
Boyuan Gu, Yu Jiang, Zhiwei Huang, et al.
International Immunopharmacology (2024) Vol. 140, pp. 112898-112898
Open Access | Times Cited: 5
PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer
Xiang Gao, Ling Yi, Chang Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma
Wenjiao Jin, Junming Yu, Yang Su, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 7, pp. 2270-2288
Open Access | Times Cited: 12
The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy
Chou‐Yi Hsu, Mustafa Nasrat Abdulrahim, Mohammed Ahmed Mustafa, et al.
Medical Oncology (2024) Vol. 41, Iss. 8
Closed Access | Times Cited: 4
The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
Dimitris Kounatidis, Nikolaοs Tentolouris, Natalia G. Vallianou, et al.
Metabolites (2024) Vol. 14, Iss. 7, pp. 388-388
Open Access | Times Cited: 4
Targeting PCSK9 in Liver Cancer Cells Triggers Metabolic Exhaustion and Cell Death by Ferroptosis
Malak Alannan, Hala Fatrouni, Véronique Trézéguet, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 62-62
Open Access | Times Cited: 19
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Emilie Wong Chong, France‐Hélène Joncas, Nabil G. Seidah, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top